Filtros de búsqueda

Lista de obras de Lukas Bunse

A vaccine targeting mutant IDH1 induces antitumour immunity

artículo científico publicado en 2014

Actively personalized vaccination trial for newly diagnosed glioblastoma

scientific article published on 19 December 2018

Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes

artículo científico publicado en 2021

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas

scientific article published on 18 February 2020

High-throughput discovery of cancer-targeting TCRs

scientific article published on 06 November 2019

Intrathecal activation of CD8<sup>+</sup> memory T cells in IgG4-related disease of the brain parenchyma

artículo científico publicado en 2021

K27M-mutant histone-3 as a novel target for glioma immunotherapy

artículo científico publicado en 2017

Nivolumab for Treatment of Progressive Multifocal Leukoencephalopathy in Sézary Syndrome

scientific article published on 09 July 2020

Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas

artículo científico publicado en 2018

Proximity ligation assay evaluates IDH1R132H presentation in gliomas

artículo científico publicado en 2015

Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway

artículo científico publicado en 2014

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

scientific article published on 09 July 2018

TCR validation toward gene therapy for cancer

scientific article published on 06 November 2019

The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway

artículo científico publicado en 2015

The promises of immunotherapy in gliomas.

artículo científico publicado en 2017

Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor

artículo científico publicado en 2016

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy

artículo científico publicado en 2013